BETHESDA, Md., Jan. 13, 2025 /PRNewswire/ -- RespondHealth, a real-world evidence (RWE) clinical discovery company, is pleased to announce a new…
ATLANTA, Jan. 13, 2025 /PRNewswire/ -- Switchboard, MD is announcing the launch of ThreatAware, an advanced solution designed to identify…
Tahoe-100M is the world's largest single-cell atlas of how drug molecules impact biology of patient cells SOUTH SAN FRANCISCO, Calif.,…
A newly published study shows Kognitic's AI reduces clinical trial primary completion date prediction errors from 508 to 179 days,…
Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at an Unprecedented Cellular Level NEW…
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform,…
Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4…
SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an…
Mark Orsmond, a highly respected business professional in Canadian Healthcare, Appointed Executive ChairMichael Nemirow Joins as Director, Bringing Decades of…
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,…